Surveyed Oncologists Expect To Prescribe Provenge To About Half Of Their Prostate Cancer Patients If The Vaccine Is Approved
Decision Res, one of the world"s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Dendreon"s Provenge receives regulatory approval, surveyed oncologists expect to prescribe Provenge to 54 percent of patients with asymptomatic hormone refractory metastatic prostate cancer. Due to the side effects associated with currently available chemotherapy, most oncologists recommend that men who have stopped responding to hormone therapy wait for the development of symptoms before starting chemotherapy.
Sexual Health